The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

William Stohl

Correspondence to Dr William Stohl

Division of Rheumatology

Los Angeles County & University of Southern California Keck School of Medicine

Los Angeles

USA;

[email]@usc.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Correspondence to Dr William Stohl, Division of Rheumatology, Los Angeles County & University of Southern California Keck School of Medicine, Los Angeles, USA;. 2003 - 2012
  • Division of Rheumatology, University of Southern California Keck School of Medicine, 2011 Zonal Avenue, HMR 711, USA. 2002 - 2012
  • Division of Rheumatology, Department of Medicine, Los Angeles County, Los Angeles, USA. 2002

References

  1. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Stohl, W., Gomez-Reino, J., Olech, E., Dudler, J., Fleischmann, R.M., Zerbini, C.A., Ashrafzadeh, A., Grzeschik, S., Bieraugel, R., Green, J., Francom, S., Dummer, W. Ann. Rheum. Dis. (2012) [Pubmed]
  2. Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development? Stohl, W. Curr. Rheumatol. Rep (2012) [Pubmed]
  3. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Stohl, W., Hiepe, F., Latinis, K.M., Thomas, M., Scheinberg, M.A., Clarke, A., Aranow, C., Wellborne, F.R., Abud-Mendoza, C., Hough, D.R., Pineda, L., Migone, T.S., Zhong, Z.J., Freimuth, W.W., Chatham, W.W. Arthritis Rheum. (2012) [Pubmed]
  4. Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity. Stohl, W., Jacob, N., Guo, S., Morel, L. Arthritis Rheum. (2010) [Pubmed]
  5. Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity. Stohl, W., Jacob, N., Quinn, W.J., Cancro, M.P., Gao, H., Putterman, C., Gao, X., Pricop, L., Koss, M.N. J. Immunol. (2008) [Pubmed]
  6. B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks?. Stohl, W., Looney, R.J. Clin. Immunol. (2006) [Pubmed]
  7. Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Stohl, W. Endocrine,. Metabolic. &. Immune. Disorders. Drug. Targets (2006) [Pubmed]
  8. BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists. Stohl, W. Curr. Dir. Autoimmun. (2005) [Pubmed]
  9. Humoral autoimmunity in mice overexpressing B cell surface CD19: vital role for MHC class II. Stohl, W., Xu, D., Kim, K.S., Tedder, T.F., Sato, S. Clin. Immunol. (2005) [Pubmed]
  10. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Stohl, W., Xu, D., Kim, K.S., Koss, M.N., Jorgensen, T.N., Deocharan, B., Metzger, T.E., Bixler, S.A., Hong, Y.S., Ambrose, C.M., Mackay, F., Morel, L., Putterman, C., Kotzin, B.L., Kalled, S.L. Arthritis Rheum. (2005) [Pubmed]
  11. MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). Stohl, W., Xu, D., Kim, K.S., David, C.S., Allison, J.P. Int. Immunol. (2004) [Pubmed]
  12. Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders. Stohl, W. Expert Opin. Ther. Targets (2004) [Pubmed]
  13. A therapeutic role for BLyS antagonists. Stohl, W. Lupus (2004) [Pubmed]
  14. Dichotomous effects of complete versus partial class II major histocompatibility complex deficiency on circulating autoantibody levels in autoimmune-prone mice. Stohl, W., Xu, D., Metzger, T.E., Kim, K.S., Morel, L., Kotzin, B.L. Arthritis Rheum. (2004) [Pubmed]
  15. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Stohl, W., Metyas, S., Tan, S.M., Cheema, G.S., Oamar, B., Roschke, V., Wu, Y., Baker, K.P., Hilbert, D.M. Ann. Rheum. Dis. (2004) [Pubmed]
  16. SLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Stohl, W. Arthritis Res. Ther. (2003) [Pubmed]
  17. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Stohl, W., Metyas, S., Tan, S.M., Cheema, G.S., Oamar, B., Xu, D., Roschke, V., Wu, Y., Baker, K.P., Hilbert, D.M. Arthritis Rheum. (2003) [Pubmed]
  18. B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases. Stohl, W. Curr. Rheumatol. Rep (2002) [Pubmed]
  19. B lymphocyte stimulator protein-associated increase in circulating autoantibody levels may require CD4+ T cells: lessons from HIV-infected patients. Stohl, W., Cheema, G.S., Briggs, W.S., Xu, D., Sosnovtseva, S., Roschke, V., Ferrara, D.E., Labat, K., Sattler, F.R., Pierangeli, S.S., Hilbert, D.M. Clin. Immunol. (2002) [Pubmed]
  20. Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein. Stohl, W. Curr. Opin. Rheumatol (2002) [Pubmed]
 
WikiGenes - Universities